{
  "id": 2122781,
  "title": "Knight Therapeutics Announces Launch of WYNZORA® in Canada",
  "url": "https://urgent.news/2026/08/20/knight-therapeutics-announces-launch-of-wynzora-in-canada",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-20T11:34:39.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/knight-therapeutics-announces-launch-of-wynzora-in-canada"
  },
  "original_language": "en",
  "account": null,
  "summary": "MONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of WYNZORA®, a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada. WYNZORA® is indicated for the topical treatment of psoriasis vulgaris in […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}